Article
Gastroenterology & Hepatology
Julien Kirchgesner, Rishi J. Desai, Maria C. Schneeweiss, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C. Kim
Summary: Combination therapy with vedolizumab and thiopurines is associated with a lower risk of treatment failure compared to vedolizumab monotherapy in patients with CD, but the effect is less pronounced in UC.
Review
Pharmacology & Pharmacy
Anuraag Jena, Chhagan L. Birda, Arup Choudhury, Vishal Sharma
Summary: Personalized testing-based initial thiopurine dosing is effective in preventing myelotoxicity compared to standard weight-based dosing.
EXPERT OPINION ON DRUG SAFETY
(2023)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Article
Gastroenterology & Hepatology
Maia Kayal, Alexa Riggs, Michael Plietz, Sergey Khaitov, Patricia Sylla, Alexander J. Greenstein, Noam Harpaz, Steven H. Itzkowitz, Shailja C. Shah
Summary: Thiopurine exposure for at least 12 weeks prior to TPC in patients with UC or IC does not appear to be independently associated with the risk of primary neoplasia following IPAA.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Review
Environmental Sciences
Oliwia Zakerska-Banaszak, Liliana Lykowska-Szuber, Michal Walczak, Joanna Zuraszek, Aleksandra Zielinska, Marzena Skrzypczak-Zielinska
Summary: The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) has been confirmed for more than 50 years. Despite controversies over their cytotoxic properties and adverse effects, thiopurines are still widely used for maintaining remission in Crohn's disease and ulcerative colitis. Further research is needed to explore the modulation of thiopurine action in combination therapy and their interaction with the gut microbiota.
Article
Gastroenterology & Hepatology
Paula Sousa, Paula Ministro, Alessandro Armuzzi, Axel Dignass, Marte Lie Hoivik, Manuel Barreiro-de Acosta, Stephan Vavricka, Rogerio Saad-Hossne, Paulo Gustavo Kotze, Laurent Peyrin-Biroulet, Fernando Magro
Summary: Majority of surveyed IBD physicians use thiopurines for treating CD and UC, considering them to have good safety profile. Despite emerging treatments, most physicians believe that thiopurines will remain an important part of the treatment algorithm for CD and UC.
DIGESTIVE AND LIVER DISEASE
(2021)
Article
Pharmacology & Pharmacy
Yang Zhang, Dandan Li, Heng Guo, Weina Wang, Xingang Li, Su Shen
Summary: This study indicated that the use of thiopurines in pregnant women with IBD does not increase the risk of congenital malformations, LBW, SGA, or spontaneous abortion, but it may be associated with an elevated risk of preterm birth when compared to IBD controls.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Review
Gastroenterology & Hepatology
Evelien M. J. Beelen, Daan Nieboer, Jeanine H. C. Arkenbosch, Miguel D. Regueiro, Jack Satsangi, Sandro Ardizzone, Antonio Lopez-Sanroman, Edoardo Savarino, Alessandro Armuzzi, C. Janneke van der Woude, Annemarie C. de Vries
Summary: This meta-analysis found that anti-TNF-alpha treatment is superior to thiopurine prophylaxis for preventing endoscopic and clinical recurrence of Crohn's disease after ileocolonic resection. This advantage was confirmed in subgroup analysis and after risk stratification.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
E. H. J. Savelkoul, M. H. J. Maas, A. R. Bourgonje, F. Crouwel, V. B. C. Biemans, N. den Broeder, M. G. V. M. Russel, T. E. H. Romkens, N. K. de Boer, G. Dijkstra, F. Hoentjen
Summary: This study compared the tolerability and drug survival of methotrexate and tioguanine therapy after failure of conventional thiopurines in patients with Crohn's disease. The results showed a higher incidence of treatment discontinuation due to adverse events for methotrexate compared with tioguanine. The incidence of total adverse events was also higher with methotrexate, while the incidence of serious adverse events was similar. These findings suggest that tioguanine may be a better choice for immunosuppressive therapy after the failure of conventional thiopurines.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Mukesh Kumar Ranjan, Sudheer Kumar Vuyyuru, Bhaskar Kante, Peeyush Kumar, Sandeep K. Mundhra, Rithvik Golla, Raju Sharma, Peush Sahni, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Summary: Approximately 50% of patients with IBD in remission would relapse after 5 years of thiopurine withdrawal. Male sex and shorter treatment duration predict relapse.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Article
Gastroenterology & Hepatology
Yoshihiro Yokota, Takayuki Imai, Masahiro Kawahara, Osamu Inatomi, Atsushi Nishida, Yoichi Kakuta, Atsushi Masamune, Akira Andoh
Summary: Thiopurines have harmful effects on testicular reproductive function according to host NUDT15 genotypes.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Line Riis Jolving, Pavithra Laxsen Anru, Jan Nielsen, Sonia Friedman, Bente Mertz Norgard
Summary: This nationwide cohort study found no increased risk of seven common chronic diseases or congenital malformations during childhood and adolescence after gestational exposure to thiopurines.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Gastroenterology & Hepatology
Mukesh Kumar Ranjan, Bhaskar Kante, Sudheer Kumar Vuyyuru, Peeyush Kumar, Sandeep K. Mundhra, Rithvik Golla, Raju Sharma, Peush Sahni, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Summary: This study retrospectively evaluated the long-term safety and efficacy of thiopurines in IBD patients in northern India, showing minimal risk of developing lymphoma or non-melanoma skin cancer.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Pharmacology & Pharmacy
Anuraag Jena, Daya Krishna Jha, Praveen Kumar-M, Kripa Shanker Kasudhan, Ankit Kumar, Dhruv Sarwal, Shubhra Mishra, Anupam Kumar Singh, Prateek Bhatia, Amol Patil, Vishal Sharma
Summary: In the South Asian population, NUDT15 polymorphisms are more prevalent than TPMT and are more frequently associated with adverse events. These findings suggest the importance of preemptive testing for NUDT15 among South Asian population and immigrants before starting thiopurines.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Review
Immunology
Reza Yarani, Ali Shojaeian, Oana Palasca, Nadezhda T. Doncheva, Lars Juhl Jensen, Jan Gorodkin, Flemming Pociot
Summary: This review discusses the differential regulation of miRNAs in inflammatory bowel disease (IBD) and their potential diagnostic and therapeutic applications. Through literature curation and computational analysis, a consensus set of differentially expressed miRNAs in mucosal tissues was obtained. The role of these miRNAs and their potential targets in IBD are highlighted.
FRONTIERS IN IMMUNOLOGY
(2022)
